Details of the Drug
General Information of Drug (ID: DM8KSMX)
Drug Name |
IMIRESTAT
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Imirestat; 89391-50-4; Imirestat [INN]; Alcon 1576; HOE 843; Imirestatum [INN-Latin]; Hoe-843; UNII-0PM69S95UQ; AL 1576; C15H8F2N2O2; AL-1576; 0PM69S95UQ; CHEMBL269455; 2,7-Difluorospiro(9H-fluorene-9,4'-imidazolidine)-2',5'-dione; Imirestatum; 2,7-Difluorospiro(fluorene-9,4'-imidazolidine)-2',5'-dione; Spiro[9H-fluorene-9,4'-imidazolidine]-2',5'-dione, 2,7-difluoro-; Spiro(9H-fluorene-9,4'-imidazolidine)-2',5'-dione, 2,7-difluoro-; AL-theta-1576; ALO1576; AL1576; SCHEMBL49034; ZINC3724; AC1L23Q8; DTXSID80237635
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 286.23 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Diabetic complication | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | 5A2Y | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References